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Summary Ten patients with small cell lung cancer were treated with high dose human lymphoblastoid
interferon (50-100 megaunitsm- 2) for 5 days, followed by low dose interferon (3 megaunitsm-2) for 3 weeks.
At the end of treatment, and one month later, there was no evidence of either complete or partial response.
The treatment produced fever, anorexia and weight loss, with transient leucopenia and thrombocytopenia;
there was evidence of a non-cholestatic elevation of serum alanine aminotransferase, with clinical deterioration
in the condition of three patients presenting with hyponatraemia. A transient hypocalcaemia during high dose
therapy was also noted. It seems that lymphoblastoid interferon as a single agent is unlikely to have a role in
the treatment of small cell lung cancer, and that its administration as employed in this study is associated with
considerable toxicity.
Small cell lung cancer remains a disease with a very
poor prognosis in spite of recent chemotherapeutic
advances (Weiss et al., 1980; Hansen, 1982). Current
results report a median survival time for intensively
treated patients of around 12 months and a 2-year
survival of 10-20%. Thus there is a clear need to
identify new and effective agents.
The anti-tumour effect of interferon-oc has been
studied in several diseases, and there have been
some reports of activity in nodular lymphocytic
lymphoma (Merigan et al., 1978; Gutterman et al.,
1980), breast cancer (Gutterman et al., 1980;
Priestman, 1980), melanoma (Priestman, 1980; Hill
et al., 1980) and myeloma (Mellstedt et al., 1979;
Gutterman et al., 1980). No activity was found in
non-small cell lung cancer (Stoopler et al., 1980),
but the greater chemosensitivity of small cell lung
cancer to other chemotherapeutic agents suggested
the need to investigate its responsiveness to
interferon. Interferon for clinical studies has usually
been derived from human leucocytes (Strander,
1977), but more recently human lymphoblastoid
interferon (HLBI) has been available (Priestman,
1980). Monoclonal antibodies may be used to purify
interferon (Secher & Burke, 1980; Scott et al.,
1982a), and interferon produced by gene cloning is
becoming available (Scott et al., 1982b). The doses
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used have been variable, but have tended to be up
to about 3 megaunits m-2. With the increasing
availability of interferon, a study of high dose
interferon in small cell cancer seemed appropriate
(Bleehen et al., 1982). This paper presents the
detailed results of a completed study in which
HLBI was administered to 10 patients. A study
using human leucocyte interferon-oc in a
modification of our protocol is currently in progress
in Helsinki (Mattson et al., 1982).
Materials and methods
Ten patients (7 male and 3 female) with
histologically and/or cytologically proven small cell
carcinoma of lung, previously untreated by
radiotherapy or chemotherapy, were studied. The
project received local ethical committee permission,
and all patients gave informed consent.
The mean age of the patients was 61 y (range 55-
66). Their clinical status was quantified according to
the Medical Research Council Performance Status
(PS) and Respiratory Status (RS) grading (Medical
Research Council Lung Cancer Working Party,
1979) (Appendix). Their disease was staged into
"limited" (tumour confined to one hemithorax, with
or without local extension, and including
mediastinal adenopathy, with or without ipsilateral
supraclavicular nodes) or "extensive" (disease
beyond the limits described). Investigations used for
staging purposes were: chest X-ray; fibreopotic/rigid
bronchoscopy; radionuclide bone scan; computed
tomography (CT) of thorax, liver and adrenals;
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bone marrow aspiration and trephine biopsy.
Patients were deemed suitable for the study only if
the extent of their disease was accurately assessable
by chest X-ray and CT measurement (and by
clinical measurements, if indicated). Pretreatment
haematological, biochemical and immunological
studies included full blood count, plasma urea,
electrolytes, creatinine and osmolarity, urine
osmolarity, liver function tests (serum protein,
albumin, calcium, bilirubin, alkaline phosphatase
and alanine aminotransferase [ALT, SGPT]),
circulating immune complexes and T cell function.
The patients were treated with human
lymphoblastoid interferon (Wellcome-"Wellferon").
This highly purified interferon-a mixture is
produced from the Namalwa cell line of Burkitt
lymphoma. It consists of a group of proteins
derived from a family of at least five structural
genes for human lymphoblastoid (leucocyte type)
interferon (Allen et al., 1980). Its specific activity
after purification, but prior to the addition of
human serum albumin as stabiliser, varies from 81-
213 x 106 IUmg-l protein. The interferon was
administered by continuous i.v. (clockwork pump)
infusion during the first 5 days of treatment. On
Days 1 and 2, 50 megaunits m-2 were administered;
on Days 3-5 inclusive, twice this dose-100
megaunitsM-2-was given. As the concentration of
the interferon varied between batches the amount
appropriate for 12h was made up to 20ml with
0.9% saline-so that the infusion syringe was
changed every 12h. Following the infusion, the
patient was given 3 megaunitsm-2 by i.m. injection,
3 x a week, commencing on Day 8, to a total of 10
injections. This resulted in the total planned
duration of treatment being one month.
During the infusion, pulse, supine blood pressure
and temperature were monitored every 4h, and any
symptoms recorded. Haemoglobin concentration,
total white cell count, platelet count, plasma
electrolytes, urea and creatinine, and plasma and
urinary osmolarity were measured daily for the first
week, and then twice weekly (or more frequently if
indicated). Liver function tests were monitored at
least twice weekly, whilst circulating immune
complexes and T cells were quantified at the end of
the infusion and at the end of treatment. In
addition, during the infusion, and for 24h following
its discontinuation, serum interferon levels were
estimated by means of a monoclonal antibody
immunoradiometric assay (Walker et al., 1982).
Chest X-rays were performed weekly, and
measurements taken to assess progression/response
of disease. One month following completion of
treatment, routine biochemical and haematological
investigations were performed, together with repeat
chest X-ray and CT scan. Disease response was
defined according to the criteria of the World
Health Organisation (1979):
Complete response disappearance of all known
disease as determined by 2 observations not less
than 4 weeks apart;
Partial response 50% or more regression in total
size of lesions (expressed as the product of 2
diameters at right angles to each other) determined
by 2 observations not less than 4 weeks apart;
No response less than 50% regression or less than
25% increase in total size of one or more lesions;
Progressive disease 25% or more increase in size of
one or more lesions, or appearance of new lesion(s).
Results
All 10 patients were in good physical condition: 9
patients were PS1, and one PS2; 6 were RS1, 3
RS2, and one RS3. Seven patients had limited
disease, and 3 extensive disease. -There was no
response seen during or after treatment with HLBI.
Two patients failed to complete the protocol
because of toxicity and these patients showed
progressive disease. Of the 8 patients who showed
no response during treatment, 6 showed progressive
disease when reassessed one month later.
Within 1-2h of commencing the infusion of
HLBI, all patients became febrile, the pyrexia
exhibiting a remittent pattern which settled towards
the end of the infusion; during the i.m. therapy the
patients' temperatures remained within normal
limits. There was fluctuation of blood pressure
during the infusion. Weakness and lethargy
occurred in all patients, whilst the 2 patients who
failed to complete their treatment also felt so
depressed that they refused further i.m. injections.
Anorexia was experienced by all patients, and
during the month of treatment the mean weight
(±lsd) fell from 70+20Kg to 64+17Kg
(0.01 <P<0.02 paired t test).
Figure 1 illustrates the changes in haemoglobin
concentration, total white cell count and platelet
count. The white cell count and platelet count fell
transiently with a recovery to normal values, the
mean nadir of the white cell being 2.2 x 10i-11 at
the end of the 4th day of the infusion (lowest
individual value 0.5 x I091-1) and the platelet count
nadir of 135 x i00l-1 occurring at 24h following
the completion of the infusion (lowest individual
value 85 x 1091-'). No clinical complication was
seen as a result of the transient leucopenia and
thrombocytopenia.INTERFERON IN SMALL CELL LUNG CANCER 363
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Figure 1 Haemoglobin concentration, total white cell count and platelet count in 10 patients during one
month's treatment with HLBI..
Circulating immune complexes (normal range 0-
24%) were unchanged during treatment: 27.7
± 11.88% (mean + lsd) pretreatment, 23.3 + 11.2% at
the end of the infusion, and 27.3+10.2% at the end
of treatment (paired analysis- no significant
difference). There was no significant difference either
in the levels of T cells (normal range 70-90%): 80.7
±13.4% (mean + lsd) pretreatment, 76.8 +8.7% at
the end of the infusion, and 80.3 + 5.0% at the end
of treatment. In all patients there was an elevation
of serum ALT during treatment, the elevation
varying between x 1.5 and x9 the upper limit of
normal, and the individual peaks all occurring
within a week following the discontinuation of the
infusion. All the values had returned to normal by
the end of the treatment.
In 6 patients, plasma electrolytes, urea, creatinine
and osmolarities remained unchanged throughout
treatment. One patient showed a transient rise in
plasma urea and creatinine levels, and this was
consistent with a pre-renal uraemia as a result of
hypotension. The renal function was rapidly
corrected with i.v. plasma expanders and loop
diuretics; glucocorticoids were not given. Three
patients with the syndrome of inappropriate ADH
secretion (SIADH), as indicated by low plasma
sodium and osmolarity with inappropriately liigh
urine osmolarity, showed marked clirnical
deterioration during HLBI infusion. One patient
became confused, drowsy and ataxic despite
demeclocycline ("Ledermycin"), and cranial CT
during this period was normal. This patient's
biochemical results are shown in the Table.
A statistically significant (P<0.001) fall in serum
calcium concentration was seen at the end of the
HLBI infusion, but this level, which was below the
lower limit of normal, returned to pretreatment
values within one week of discontinuation of the
infusion.
Following commencement of the infusion, the364 D.H. JONES et al.
Table Summary of plasma sodium levels and plasma and urine
osmolarities in a patient with the syndrome of inappropriate ADH, and
who was treated with HLBI.
*Pre Last day of Last day of
treatment HL BI infusion HLBI treatment
Plasma sodium
(mmol/l) 118 109 137
Plasma osmolarity
(mmol/l) 245 232 283
Urine osmolarity
(mmol/l) 715 550 303
*One day before starting
300mg TDS was commenced.
HLBI infusion-when demeclocycline
| H.L.B.I. Infusion
50 megaunits/m2l 100 megaunits mr2
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Discussion
The treatment with HLBI of 10 patients with
assessable small cell lung cancer in this Phase II
study resulted in no tumour response during
therapy, with some progression of disease during
the month following the end of treatment. The use
of an induction regime utilising high doses followed
by a maintenance regime using more conventional
doses therefore resulted in no anti-tumour effect,
but was associated with considerable toxicity.
Reports on toxicity (Priestman, 1980) have indicated
that fever, fatigue and malaise, thrombocytopenia
and leucopenia are almost inevitably associated
with interferon treatment, and there have been
suggestions that such complications are dose
related. The large infusion doses given in the
248 h 4812 h present study result in high serum interferon levels
o 1 2 3 4 5 6 (600-900uml-') but do not seem to cause more
Days after starting H.L.B.I. severe subjective toxicities than the lower dose
regimes previously described (Priestman, 1980)
Serum HLBI concentrations in 10 patients when serum levels of 150uml-' were recorded. It is
2-day infusion of 50 megaunitsm-2 possible that subjective toxicity varies with
tely followed by 3-day infusion of 100 individual patients and does not show a direct
tsM-2. relationship to dose. In one study (Rohatiner et al.,
1982) using high doses of up to 200
megaunitsm-2 life-threatening complications were
described, and the authors have suggested that the
,els of interferon rapidly reached a plateau maximum safely tolerated daily dose should not
.s maintained until the dose was increased exceed 100 megaunitsm-2 given by continuous i.v.
3rd day. This new plateau was further infusion over 7 days. We are unaware of previous
d until the infusion was discontinued, reports of the exacerbation of SIADH by interferon,
serum levels fell rapidly with a half life of but the fact that 3/10 patients in the present study
ling the infusion dose resulted in a rise in showed clinical deterioration of their condition,
concentration from around 600uml-' to with concomitant worsening of the plasma and
)uml-'. These results are shown in Figure urinary biochemical indices, suggests that the drug
should not be given to patients with dilutional
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hyponatraemia. It is difficult to propose a
mechanism by which interferon causes this
disturbance, and an attempt to monitor the plasma
ADH levels serially in the patient described in the
Table failed due to technical problems in the
laboratory.
Abnormalities of some liver function tests have
been described with interferon, whether it is used as
an antiviral or anti-inflammatory agent (Jordan et
al., 1974; Greenberg et al., 1976; Kajander et al.,
1979) or in the treatment of malignancy (Osserman
et al., 1980; Krown et al., 1980), with an incidence
from 20-100%. Our study demonstrates that the
elevated ALT values return to normal within 2
weeks, despite the continuation of treatment. It
seems that the abnormality is unlikely to be dose
related, or associated with cholestasis, as serum
bilirubin and alkaline phosphatase showed no
change.
The leucopenia may be associated with the
process of margination that is known to occur with
an acute inflammatory response (Robbins &
Cotran, 1979). The transient nature of the change,
and the return to normal despite continuation of
treatment would support this hypothesis. No
complications such as bleeding or infections
occurred in association with the nadir values so
that there was no indication to discontinue
treatment. The hypocalcaemia observed at the end
of the infusion caused no clinical problems, and its
mechanism remains unexplained.
The serum levels of interferon indicate that
plateau levels may be maintained satisfactorily with
continuous intravenous infusions of the drug. The
results in Figure 2 show that the drug is rapidly
cleared from the plasma. Our studies on the serum
levels in one patient following a single i.m. dose of
HLBI indicated concentrations similar to values
already published (Walker et al., 1982). In those
malignancies that have shown some response to
interferon, there is no evidence to indicate that this
is directly related to serum levels. The relationship
between cell survival and human leucocyte
interferon concentration in vitro has been repeated
in one study using a human tumour cloning assay
for several different tumours (Von Hoff et al., 1982).
Tumour from 2 patients with small cell cancer of
the lung showed a reduction in colony survival at
interferon concentrations of 500-1000uml- '-levels
of the same order as those achieved in the plasma
of our patients. However, a further 3 showed no
significant response even at the highest drug dosage.
Despite our ability to maintain high serum levels by
means of the infusion, the tumours under study
failed to exhibit any response. It is possible of
course that the duration of treatment was
inadequate but we felt unable to continue for longer
in the absence of positive response.
The observation of no response in 10 patients is
sufficient to exclude the possibility of a true 25%
response rate at the 5% level of statistical
significance [(1-0.25)1o=0.056]. Phase II studies
conventionally include 14 patients so as to exclude
a 20% response rate, but because of the toxicity and
lack of response in the current 10 patients, we did
not believe that we were ethically justified in
including more previously untreated patients.
From our experience we feel that human
lymphoblastoid interferon as a single agent has no
role in the treatment of small cell cancer of the
lung. Its toxicities are as major as, and sometimes
greater than, the combination chemotherapy
regimes that are now used with some success for
small cell lung cancer. Whether other interferons
will be of more benefit remains to be assessed.
We appreciate very helpful discussions with Drs. T.J.
Priestman and J.L. Toy, Department of Clinical
Immunology and Chemotherapy, Clinical Research
Division, Wellcome Research Laboratories, Beckenham,
Kent. They also very generously supplied the HLBI. Mr.
L.S. Freedman gave helpful advice regarding the statistical
aspects of the study. We wish to thank all referring
clinicians, the staff of the investigational departments of
Addenbrooke's Hospital who performed the various
routine laboratory tests, and Dr. D.S. Secher, Medical
Research Council Laboratory of Molecular Biology,
Cambridge, who kindly supplied the monoclonal anti-
human interferon-a antibody used in the serum assay.
Appendix
S
S
core Performance Status
1 At work or active retirement
2 Full activity but not at work, or can do
light work only
3 Out and about but activity restricted
4 Confined to home/hospital
5 Fully disabled-permanently confined to
bed/chair
,core Respiratory Status
1 Clinibs hills and stairs without dyspnoea
2 Walks any distance on flat without
dyspnoea
3 Walks more than 100 yards at own pace
without dyspnoea
4 Dyspnoea on walking 100 yards or less
5 Dysponea on mild exertion,
e.g. undressing.
Scoring systems (Medical Research Council scale
[MRC Lung Cancer working party, 1979]) to
determine Performance Status (PS) and Respiratory
Status (RS) of patients treated with HLBI.366 D.H. JONES et al.
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